TNXP.NASDAQTonix Pharmaceuticals Holding CORP
10-Q: Tonix Pharmaceuticals Reports Q2 2024 Results, Faces Going Concern Uncertainty Amidst Strategic Shift
Sentiment:
Quarterly Report
Tonix Pharmaceuticals reported its Q2 2024 results, including a significant net loss and asset impairments, while also expressing substantial doubt about its ability to continue as a going concern.
Capital raiseThe company has raised additional capital through equity offerings, but management believes that current resources will not meet operating and capital expenditure requirements beyond the third quarter of 2024.The company has the ability to obtain additional funding through public or private financing or collaborative arrangements with strategic partners to increase the funds available to fund operations.The company entered into a Sales Agreement with AGP pursuant to which the Company may issue and sell, from time to time, shares of the Companys common stock having an aggregate offering price of up to $50.0 million in ATM sales.The company sold 3,393,600 shares of common stock and pre-funded warrants to purchase up to 3,703,140 shares of common stock on July 9, 2024 for net proceeds of approximately $3.5 million.
Worse than expectedThe company's net loss was significantly higher than the previous year.The company recorded a substantial non-cash impairment charge, indicating a decline in asset value.Management has expressed substantial doubt about the company's ability to continue as a going concern.
Summary
- Tonix Pharmaceuticals reported a net loss of $78.8 million for the three months ended June 30, 2024, and a net loss of $93.7 million for the six months ended June 30, 2024.
- The company's revenue for the quarter was $2.2 million and $4.7 million for the six month period, primarily from sales of Zembrace SymTouch and Tosymra.
- A significant non-cash impairment charge of $58.9 million was recorded, including $48.8 million related to property and equipment, $1.0 million related to goodwill, and $9.2 million related to intangible assets.
- Research and development expenses decreased to $9.7 million for the quarter and $22.6 million for the six month period, reflecting a strategic prioritization of the TNX-102 SL program.
- The company's working capital was approximately $3.2 million as of June 30, 2024, and cash and cash equivalents were $4.2 million.
- Tonix has raised additional capital through equity offerings, but management believes that current resources will not meet operating and capital expenditure requirements beyond the third quarter of 2024.
- There is substantial doubt about the company's ability to continue as a going concern without additional funding.
Sentiment
Score: 2
Explanation: The document indicates significant financial distress, substantial losses, and a going concern warning, which are all highly negative indicators for investors. The company's future is uncertain, and there are significant risks associated with its ability to continue operations.
Positives
- Tonix is prioritizing the submission of a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia in the second half of 2024.
- The company has a commercial infrastructure in place from the acquisition of Zembrace and Tosymra, which could be leveraged for future product launches.
- Tonix has received a $3 million grant from the U.S. Department of Defense for a trial of TNX-102 SL for Acute Stress Reaction.
- The company has a contract for up to $34 million from the DoD for the development of TNX-4200, a broad-spectrum antiviral.
Negatives
- The company reported a significant net loss of $78.8 million for the quarter and $93.7 million for the six month period.
- A substantial non-cash impairment charge of $58.9 million was recorded, indicating a significant write-down of assets.
- The company's working capital is low at $3.2 million, and cash reserves are at $4.2 million.
- Management has expressed substantial doubt about the company's ability to continue as a going concern.
- The company has delayed investment in sales personnel for its commercialized products, impacting revenue growth.
Risks
- The company faces significant challenges and uncertainties regarding its ability to secure additional funding.
- There is a risk that the company may be forced to delay, scale back, or eliminate research and development activities.
- The company may default under the terms of its existing indebtedness.
- The company's ability to achieve development and commercialization goals is at risk.
- The company's stock may be delisted from Nasdaq if it does not regain compliance with the minimum bid price requirement.
Future Outlook
The company anticipates that its existing cash and cash equivalents, along with proceeds from recent equity offerings, will enable it to maintain operations into the third quarter of 2024, but not beyond. The company will need to obtain additional capital to fund future research and development activities and future capital expenditures.
Management Comments
- Management believes that the benefits and long-term value proposition of the 2023 acquisition of Tosymra and Zembrace remain, in that we now have the infrastructure to be ready to manufacture and sell TNX-102 SL under an expedited timeline pending FDA approval for which we expect an FDA decision in 2025.
- Management has expressed substantial doubt about the company's ability to continue as a going concern for the one year period from the date of filing of this Form 10-Q.
Industry Context
The company's focus on central nervous system (CNS) disorders and infectious diseases aligns with current trends in the pharmaceutical industry. The development of TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication addresses unmet medical needs. The company's commercialization of Zembrace and Tosymra provides a foundation for future product launches.
Comparison to Industry Standards
- The significant impairment charges recorded by Tonix are unusual compared to industry standards, suggesting potential issues with asset valuation or market performance.
- The company's cash burn rate and going concern warning are concerning and indicate a need for significant financial restructuring or capital infusion, which is not typical for companies with commercialized products.
- While the company has a diverse pipeline, the lack of profitability and the need for continuous capital raises are not in line with industry benchmarks for companies at a similar stage of development.
- Compared to companies like Teva or Amgen, which have established revenue streams and diverse product portfolios, Tonix is in a much more precarious financial position.
- The company's reliance on government grants and contracts for funding is also a deviation from the norm, as most established pharmaceutical companies rely on product sales and private investment.
Stakeholder Impact
- Shareholders face significant risk of loss due to the company's financial instability and going concern warning.
- Employees may face job insecurity due to potential restructuring or downsizing.
- Customers may experience uncertainty regarding the availability of the company's products.
- Suppliers and creditors face increased risk of non-payment.
- The company's ability to continue research and development may be impacted, affecting future product development.
Next Steps
- The company plans to submit a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia in the second half of 2024.
- The company will need to secure additional funding to continue operations beyond the third quarter of 2024.
- The company will need to regain compliance with Nasdaq's minimum bid price requirement to avoid delisting.
Key Dates
| Date | Description |
|---|---|
| 2019-05-02 | Date of Tonix Pharmaceuticals Holdings Corp. 2023 Employee Stock Purchase Plan |
| 2019-05-03 | Date of Tonix Pharmaceuticals Holdings Corp. 2023 Employee Stock Purchase Plan |
| 2020-04-07 | Date of Sales Agreement with Alliance Global Partners |
| 2020-04-08 | Date of Sales Agreement with Alliance Global Partners |
| 2020-05-01 | Date of Amended and Restated 2020 Plan |
| 2020-09-27 | Date of purchase of Advanced Development Center |
| 2020-09-28 | Date of purchase of Advanced Development Center |
| 2020-09-29 | Date of purchase of Advanced Development Center |
| 2020-12-21 | Date of purchase of Hamilton, Montana site |
| 2020-12-23 | Date of purchase of Hamilton, Montana site |
| 2021-09-22 | Date of purchase of Frederick, Maryland R&D facility |
| 2021-10-01 | Date of purchase of Frederick, Maryland R&D facility |
| 2022-08-15 | Date of Purchase Agreement with Lincoln Park Capital Fund, LLC |
| 2022-08-16 | Date of Purchase Agreement with Lincoln Park Capital Fund, LLC |
| 2023-01-01 | Start of Share Repurchase Program 2022 |
| 2023-01-31 | End of Employee Stock Purchase Plan 2022 |
| 2023-02-01 | Date of Asset Purchase Agreement with Healion Bio Inc. |
| 2023-02-02 | Date of Asset Purchase Agreement with Healion Bio Inc. |
| 2023-03-27 | Date of Sales Agreement |
| 2023-03-28 | Date of Sales Agreement |
| 2023-03-31 | End of Share Repurchase Program 2022 and 2023 |
| 2023-04-01 | Start of Purchase Agreement with Lincoln Park Capital Fund, LLC |
| 2023-06-29 | Date of Asset Purchase Agreement with Upsher Smith Laboratories, LLC |
| 2023-06-30 | Date of Asset Purchase Agreement with Upsher Smith Laboratories, LLC |
| 2023-07-26 | Date of Sales Agreement |
| 2023-07-27 | Date of Sales Agreement |
| 2023-07-31 | Date of Sales Agreement |
| 2023-08-01 | Date of Sales Agreement |
| 2023-10-02 | Date of Sales Agreement |
| 2023-10-03 | Date of Sales Agreement |
| 2023-12-07 | Date of Term Loan Agreement |
| 2023-12-08 | Date of Term Loan Agreement |
| 2023-12-19 | Date of Purchase Agreement |
| 2023-12-20 | Date of Purchase Agreement |
| 2024-01-25 | Shareholder approval to increase authorized shares |
| 2024-03-27 | Date of Sales Agreement |
| 2024-03-28 | Date of Sales Agreement |
| 2024-04-01 | Date of Warrant Amendments |
| 2024-05-22 | Shareholder approval of Warrant Amendments |
| 2024-06-01 | Start of Employee Stock Purchase Plan 2023 |
| 2024-06-10 | Date of Reverse Stock Split |
| 2024-06-11 | Date of Purchase Agreement |
| 2024-06-12 | Date of Purchase Agreement |
| 2024-06-26 | Date of Purchase Agreement |
| 2024-06-27 | Date of Purchase Agreement |
| 2024-06-30 | End of Quarter |
| 2024-07-01 | Start of Employee Stock Purchase Plan 2023 |
| 2024-07-08 | Date of Purchase Agreement |
| 2024-07-09 | Date of Purchase Agreement |
| 2024-07-29 | Date of Sales Agreement with Alliance Global Partners |
| 2024-07-30 | Date of Sales Agreement with Alliance Global Partners |
| 2024-08-08 | Date of Nasdaq letter regarding minimum bid price |
| 2024-08-09 | Date of Nasdaq letter regarding minimum bid price |
| 2024-08-16 | Date of report |
Keywords
TNX-102 SL, Fibromyalgia, Pharmaceuticals, Biotechnology, Impairment, Going Concern, Net Loss, Research and Development, Zembrace, Tosymra, FDA, Capital Raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.